Scholarlink

Background <p>The global resurgence of cholera, a diarrhoeal disease, has resulted in vaccine demand that exceeds the currently available supply resulting in global calls for next generation cholera vaccines. DuoChol is a novel, thermostable, low-cost oral cholera vaccine capsule currently in development which has the potential to introduce programmatic benefits and efficiencies in cholera vaccination campaigns.</p> Objectives <p>This qualitative study aimed to identify country-specific challenges in handling, distributing, and storing cholera vaccines and to assess the feasibility, acceptability, and policy implications of vaccine capsules compared to current products and practices in vaccination campaigns.</p> Methods <p>Using the World Health Organization’s Vaccine Innovation Framework, consultations were conducted with 81 immunization programme stakeholders from Bangladesh, Ethiopia, Kenya, Mozambique and Tanzania.</p> Results <p>Key barriers to cholera vaccination include challenges in disbursing funds to subnational levels and the need for surged resources, such as additional health workers and cold chain equipment, during campaigns. Stakeholders discussed attributes of the novel vaccine such as improved thermostability and presentation which could reduce or eliminate the existing barriers.</p> Conclusions <p>The stakeholders highlighted that vaccine capsules are desirable for use in the general population as they have the potential to have many advantages over the current practice. However, for children who are not able to swallow the capsule, the currently available liquid oral cholera vaccine may be more desirable. To make an eventual informed decision about whether to recommend use of the vaccine capsule, national stakeholders requested the generation of evidence derived from pilot studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Uptake likelihood assessment of oral cholera vaccine capsules: insights from stakeholder consultations in five countries

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Dijana Spasenoska,
  • Anna-Lea Kahn,
  • Malika Bouhenia,
  • Naveena Aloysia D’Cor,
  • Jung-Seok Lee,
  • Se Eun Park,
  • Julia Lynch

摘要

Background

The global resurgence of cholera, a diarrhoeal disease, has resulted in vaccine demand that exceeds the currently available supply resulting in global calls for next generation cholera vaccines. DuoChol is a novel, thermostable, low-cost oral cholera vaccine capsule currently in development which has the potential to introduce programmatic benefits and efficiencies in cholera vaccination campaigns.

Objectives

This qualitative study aimed to identify country-specific challenges in handling, distributing, and storing cholera vaccines and to assess the feasibility, acceptability, and policy implications of vaccine capsules compared to current products and practices in vaccination campaigns.

Methods

Using the World Health Organization’s Vaccine Innovation Framework, consultations were conducted with 81 immunization programme stakeholders from Bangladesh, Ethiopia, Kenya, Mozambique and Tanzania.

Results

Key barriers to cholera vaccination include challenges in disbursing funds to subnational levels and the need for surged resources, such as additional health workers and cold chain equipment, during campaigns. Stakeholders discussed attributes of the novel vaccine such as improved thermostability and presentation which could reduce or eliminate the existing barriers.

Conclusions

The stakeholders highlighted that vaccine capsules are desirable for use in the general population as they have the potential to have many advantages over the current practice. However, for children who are not able to swallow the capsule, the currently available liquid oral cholera vaccine may be more desirable. To make an eventual informed decision about whether to recommend use of the vaccine capsule, national stakeholders requested the generation of evidence derived from pilot studies.